Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Grist

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Urologic Oncology|May 31, 2015
The development of abiraterone acetate for castration-resistant prostate cancerEmily Grist, Gerhardt Attard
The Journal of Steroid Biochemistry and Molecular Biology|September 25, 2014
Targeting extra-gonadal androgens in castration-resistant prostate cancerEmily Grist, Johann S de Bono, Gerhardt Attard
The Clinical Respiratory Journal|February 21, 2020
Pulsed echinocandin therapy in azole intolerant or multiresistant chronic pulmonary aspergillosis: A retrospective review at a UK tertiary centreWilliam Osborne, Michelle Fernandes, Sophie Brooks, et al.
European Urology|April 2, 2014
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abirateronePraful Ravi, Joaquin Mateo, David Lorente, et al.
Science Translational Medicine|September 19, 2014
Tumor clone dynamics in lethal prostate cancerSuzanne Carreira, Alessandro Romanel, Jane Goodall, et al.
Molecular Cancer Research : MCR|June 22, 2026
ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancerFrancesca Lorenzin, Giulia Fracassi, Federico Vannuccini, et al.
Nature Communications|August 10, 2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clonesA M Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, et al.
European Urology|December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateRoberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
JAMA Oncology|February 27, 2025
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical TrialGianmarco Leone, Francesco Orlando, Peter Dutey-Magni, et al.
The Journal of Clinical Investigation|March 31, 2026
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancerLarissa Mendes, Peter F Dutey-Magni, Emily Grist, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Urologic Oncology|May 31, 2015
The development of abiraterone acetate for castration-resistant prostate cancerEmily Grist, Gerhardt Attard
The Journal of Steroid Biochemistry and Molecular Biology|September 25, 2014
Targeting extra-gonadal androgens in castration-resistant prostate cancerEmily Grist, Johann S de Bono, Gerhardt Attard
The Clinical Respiratory Journal|February 21, 2020
Pulsed echinocandin therapy in azole intolerant or multiresistant chronic pulmonary aspergillosis: A retrospective review at a UK tertiary centreWilliam Osborne, Michelle Fernandes, Sophie Brooks, et al.
European Urology|April 2, 2014
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abirateronePraful Ravi, Joaquin Mateo, David Lorente, et al.
Science Translational Medicine|September 19, 2014
Tumor clone dynamics in lethal prostate cancerSuzanne Carreira, Alessandro Romanel, Jane Goodall, et al.
Molecular Cancer Research : MCR|June 22, 2026
ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancerFrancesca Lorenzin, Giulia Fracassi, Federico Vannuccini, et al.
Nature Communications|August 10, 2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clonesA M Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, et al.
European Urology|December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateRoberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
JAMA Oncology|February 27, 2025
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical TrialGianmarco Leone, Francesco Orlando, Peter Dutey-Magni, et al.
The Journal of Clinical Investigation|March 31, 2026
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancerLarissa Mendes, Peter F Dutey-Magni, Emily Grist, et al.
Pageof 2